04.11.2024 22:41:37
|
Vertex Pharmaceuticals Inc. Q3 Profit Increases, Beats Estimates
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) released a profit for its third quarter that increased from the same period last year and beat the Street estimates.
The company's bottom line came in at $1.045 billion, or $4.01 per share. This compares with $1.035 billion, or $3.97 per share, in last year's third quarter.
Excluding items, Vertex Pharmaceuticals Inc. reported adjusted earnings of $1.143 billion or $4.38 per share for the period.
Analysts on average had expected the company to earn $4.14 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 11.6% to $2.771 billion from $2.483 billion last year.
Vertex Pharmaceuticals Inc. earnings at a glance (GAAP) :
-Earnings (Q3): $1.045 Bln. vs. $1.035 Bln. last year. -EPS (Q3): $4.01 vs. $3.97 last year. -Revenue (Q3): $2.771 Bln vs. $2.483 Bln last year.
-Guidance: Full year revenue guidance: $10.8 - $10.9 Bln
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
31.01.25 |
Schwacher Handel in New York: NASDAQ Composite schließt in der Verlustzone (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: Pluszeichen im NASDAQ 100 (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: NASDAQ Composite-Börsianer greifen am Freitagnachmittag zu (finanzen.at) | |
31.01.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite-Anleger greifen zu (finanzen.at) | |
31.01.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 legt am Mittag zu (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 mit positivem Vorzeichen (finanzen.at) |
Analysen zu Vertex Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Vertex Pharmaceuticals Inc. | 444,40 | 5,26% |